Literature DB >> 22550068

Ca(2+)-dependent desensitization of insulin secretion by strong potassium depolarization.

M Willenborg1, M Belz, K Schumacher, A Paufler, K Hatlapatka, I Rustenbeck.   

Abstract

Depolarization by a high K(+) concentration is a widely used experimental tool to stimulate insulin secretion. The effects occurring after the initial rise in secretion were investigated here. After the initial peak a fast decline occurred, which was followed by a slowly progressive decrease in secretion when a strong K(+) depolarization was used. At 40 mM KCl, but not at lower concentrations, the decrease continued when the glucose concentration was raised from 5 to 10 mM, suggesting an inhibitory effect of the K(+) depolarization. When tolbutamide was added instead of the glucose concentration being raised, a complete inhibition down to prestimulatory values was observed. Equimolar reduction of the NaCl concentration to preserve isoosmolarity enabled an increase in secretion in response to glucose. Unexpectedly, the same was true when the Na(+)-reduced media were made hyperosmolar by choline chloride or mannitol. The insulinotropic effect of tolbutamide was not rescued by the compensatory reduction of NaCl, suggesting a requirement for activated energy metabolism. These inhibitory effects could not be explained by a lack of depolarizing strength or by a diminished free cytosolic Ca(2+) concentration ([Ca(2+)](i)). Rather, the complexation of extracellular Ca(2+) concomitant with the K(+) depolarization markedly diminished [Ca(2+)](i) and attenuated the inhibitory action of 40 mM KCl. This suggests that a strong but not a moderate depolarization by K(+) induces a [Ca(2+)](i)-dependent, slowly progressive desensitization of the secretory machinery. In contrast, the decline immediately following the initial peak of secretion may result from the inactivation of voltage-dependent Ca(2+) channels.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22550068     DOI: 10.1152/ajpendo.00010.2012

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  6 in total

1.  Pancreatic β-cell-specific ablation of TASK-1 channels augments glucose-stimulated calcium entry and insulin secretion, improving glucose tolerance.

Authors:  Prasanna K Dadi; Nicholas C Vierra; David A Jacobson
Journal:  Endocrinology       Date:  2014-06-16       Impact factor: 4.736

2.  Gap junction proteins in the blood-brain barrier control nutrient-dependent reactivation of Drosophila neural stem cells.

Authors:  Pauline Spéder; Andrea H Brand
Journal:  Dev Cell       Date:  2014-07-24       Impact factor: 12.270

3.  A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone.

Authors:  Ok-Ryul Song; Han-Byul Kim; Samuel Jouny; Isabelle Ricard; Alexandre Vandeputte; Nathalie Deboosere; Estelle Marion; Christophe J Queval; Pierre Lesport; Emmanuel Bourinet; Daniel Henrion; Seog Bae Oh; Guillaume Lebon; Guillaume Sandoz; Edouard Yeramian; Laurent Marsollier; Priscille Brodin
Journal:  Toxins (Basel)       Date:  2017-07-18       Impact factor: 4.546

Review 4.  The changing view of insulin granule mobility: From conveyor belt to signaling hub.

Authors:  Bastian Gaus; Dennis Brüning; Sofie Groß; Michael Müller; Ingo Rustenbeck
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-02       Impact factor: 6.055

Review 5.  What Is the Metabolic Amplification of Insulin Secretion and Is It (Still) Relevant?

Authors:  Ingo Rustenbeck; Torben Schulze; Mai Morsi; Mohammed Alshafei; Uwe Panten
Journal:  Metabolites       Date:  2021-06-02

6.  Culture on a native bone marrow-derived extracellular matrix restores the pancreatic islet basement membrane, preserves islet function, and attenuates islet immunogenicity.

Authors:  Hanzhou Wang; Shengxian Li; Qiuxia Dai; Aaron Gonzalez; Olivia N Tran; Haiyan Sun; Ralph A DeFronzo; David D Dean; Chih-Ko Yeh; Xiao-Dong Chen
Journal:  FASEB J       Date:  2020-04-19       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.